SS is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands that may occur alone (primary SS) or with a comorbid autoimmune condition (secondary SS). Symptomatic therapies to treat dry eyes, dry mouth, or specific extraglandular manifestations are the cornerstone of disease management. Systemic manifestations are most often treated with hydroxychloroquine or, in severe cases, systemic immunomodulators (e.g., azathioprine, methotrexate). Dry eye in SS is treated with eye drops (e.g., Novartis’s Xiidra); dry mouth is treated with artificial saliva or muscarinic receptor agonists. Therapies with disease-modifying potential are in development for SS, targeting key pathways believed to drive pathological processes in the disease. These putative disease-modifying therapies have the potential to transform the management of SS, although SS is an indication in which success has historically proven to be a challenge.
- How large is the SS population, and how will its size change over time?
- How is SS currently managed? Which drugs are the most important, and what drives their use?
- Which unfulfilled clinical needs are the most pressing?
- Which pipeline products are the most promising (e.g., Novartis’s iscalimab), and what sales might they garner in the SS market? What therapies of note are progressing in earlier phases?
- What are the drivers and constraints in the SS market, and how will the market evolve through 2028?
- Geographies: United States and EU5
- Primary Research: Six country-specific interviews with thought-leading rheumatologists supported by survey data collected for this study
- Epidemiology: Diagnosed and drug-treated prevalent cases of SS by country, prevalence of primary SS
- Forecast: Drug-level sales and patient share of key SS therapies in 2018 and 2028
- Emerging Therapies: Phase II: 9 drugs; coverage of select preclinical and Phase I products